cytochrome P450, family 2, subfamily c, polypeptide 24
RGD ID:
1563697
Description:
Predicted to enable heme binding activity and monooxygenase activity. Predicted to be involved in organic acid metabolic process and xenobiotic metabolic process. Predicted to act upstream of or within arachidonate metabolic process and linoleic acid metabolic process. Predicted to be located in endoplasmic reticulum membrane. Predicted to be active in cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including Plasmodium falciparum malaria; carcinoma (multiple); eosinophilic esophagitis; glucose metabolism disease (multiple); and heroin dependence. Orthologous to several human genes including CYP2C18 (cytochrome P450 family 2 subfamily C member 18); INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; acetamide.
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA more ...
NR1I2 gene mutant form inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA] and NR1I2 protein promotes the reaction [Pregnenolone Carbonitrile results in increased expression of CYP2C55 mRNA]
[Succimer binds to Magnetite Nanoparticles] which results in increased expression of CYP2C55 mRNA and [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of CYP2C55 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA